Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Conference on Smoking Cessation 2008 : BharatBook.com30TH - 31ST JANUARY 2008, BSG CONFERENCE CENTRE, LONDON, UK Developing and evaluating smoking cessation treatments The anti-smoking product market is on the verge of success
Tobacco consumption remains the most important avoidable cancer risk and smoking causes 90% of all lung cancers. The vast majority of cigarette smokers who try to quit ultimately fail because of high relapse rates. Our first Smoking Cessation could not be more timely. With the first prescription medication approved in almost a decade for smoking cessation and recent smoking bans in countries, especially in England. The anti-smoking pipeline looks promising with a total of 17 drugs with new targets. The launch of new therapies, such as the vaccines and MAO inhibitors, expected to hit the market in late 2009 and early 2010 will have a major impact on the overall drive of the market in terms of revenue. As health authorities seek to reduce overall healthcare expenditure on smoking related disorders. The Smoking Cessation conference will provide the ideal strategic forum for researchers, clinicians, pharma, and biotech to examine current and future smoking cessation therapies, and assess the factors influencing the market, from new product developments to distribution and pricing issues. Reasons to register today : Explore the prospects for long term efficacy of new classes of no nicotinic drugs in development Identify novel therapeutic targets to improve smoking cessation Examine potential market opportunities for new anti-smoking products Discuss the regulatory considerations for therapeutic vaccination Increase the cost-effectiveness and benefi ts of smoking cessation aids Hear from expert figures of all areas of the industry, collaborating and sharing knowledge at one venue I look forward to meeting you at the conference Best regards Andrea Charles Conference Producer Pharmaceutical Division ------------------------------------------------------------ Who will be there? Companies : Pharmaceutical and biotech companies Academics Regulatory organisations Trade organisations Healthcare professionals VPs, Directors, Heads and Managers of : Research and Development Business Development Commerical development Clinical Trials Clinical Pharmacology Drug Delivery Smoking Cessation/ Anti-smoking products Outcomes Research Pricing Reimbursement and Access Marketing Product management ------------------------------------------------------------ Day 1 - SMOKING CESSATION 2008 - WEDNESDAY 30TH JANUARY 2008 09:00 Registration & refreshments 09:30 Chairs’ opening remarks 09:40 Examining the current market potential for new anti-smoking products • Identifying market drivers and restraints • Nicotine Replacement Therapy (NRT): The current heavyweight! • Can any product compete with a OTC nicotine gum? • The antidepressant approach: Bupropion (Zyban) • Pfizer’s Chantix / Champix • Sanofi ’s Dianicline • Future contenders: - nicotine metabolism inhibitors - nicotine vaccines 10.20 Developing therapeutic vaccinations for smoking cessation • Therapeutic benefi ts: Cigarette smoking has been identified as the most important source of preventable morbidity and premature mortality worldwide • Examining current therapies and the requirement for a novel strategy of treatment • Overview of the therapeutic vaccines against smoking • Pre-clinical and clinical evidence to support the induction of antibodies to nicotine and the regulatory hormones involved • Regulatory compliance Martin Bachmann Executive Vice President & Chief Executive Officer Cytos Biotechnology* 11:00 Morning refreshments 11.20 NicVax: Next steps • NicVAX® (Nicotine Conjugate Vaccine) is an investigational • Vaccine designed as an aid to smoking cessation, as well as an aid to prevent relapses of a treated smoker • Overview of key findings to date • Complete Phase 2b trial and 12-month data analysis • Complete design of optimal protocol Dr Matthew W Kalnik Vice President, Business Development and Project Management Nabi Biopharmaceuticals 12:10 Varenicline: • Varenicline: • Varenicline is an 4 2 nicotinic acetylcholine receptor partial agonist. • Reducing the satisfaction of continued smoking • Producing partial activation at nicotinic receptors to ease craving and withdrawal symptoms • Simultaneously blocking the effects of nicotine from cigarettes smoked • Effi cacy and safety of varenicline for smoking cessation Alex Bobak GP Wandsworth PCT London* 12:50 Networking lunch 14.10 Rimonabant for smoking cessation • What is rimonabant ? • What is the evidence for its use in smoking cessation ? • Could it prevent weight gain after smoking ? • How safe is it? Kate Cahill Review group co-ordinator Cochrane Tobacco Addiction Group 14.50 The impact of smoking cessation on the course of respiratory disease • Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy • The need for effective smoking cessation strategies • Smoking and COPD: patients with COPD, an annual quit rate of around 15% • Development of smoking cessation interventions for people with COPD • Prospects for long term effi cacy of new classes of non-nicotinic drugs in development Professor Philip Tønnesen Chair, dept Pulmonary Medicine Gentofte University Hospital 15:30 Afternoon refreshments 15:50 Smoking cessation in primary care Dr Anders Østrem General Practitioner President, International Primary Care Respiratory Group 16:30 Maintaining a critical competitive advantage • Marketing approach of the tobacco industry • What they do well to attract customers • Utilising what they do well to beat them at their own game Keith Burnett Delivery Manager (North) Department of Health Tobacco Control National Support Team 17.10 Chair’s closing remarks 17.20 Networking Drinks Take your discussions further and build new relationships in a relaxed and informal setting. For more information kindly visit: http://www.bharatbook.com/ # # # BharatBook, the leading information aggregator. We facilitate and support the business information needs. With over 90,000 reports, you can get instant access and insights on the studies in you for market research, corporate / strategic planning by providing the latest information in the form of reports, journals, magazines and databases on varied industries like automotive, oil and gas, shipping, textiles, pharmaceuticals, energy, banking, finance, insurance, risk management Website: www.bharatbook.com End
|
| |||||||||||||||||||||||||||||||||||||||||||||||
